Endocrine Pharmacology USMLE Step 1 Practice Question

A 66-year-old woman with type 2 diabetes mellitus presents with a fasting glucose of 156 mg/dL and HbA1c of 8.2%. She is overweight (BMI 31) and seeks an oral agent that increases endogenous incretin activity without promoting weight gain. Her vital signs are stable (BP 138/82, HR 78, RR 16). Renal function is preserved with a creatinine of 0.9 mg/dL and eGFR of 72 mL/min/1.73m². Physical exam reveals no peripheral edema. She denies gastrointestinal symptoms. The prescriber selects a medication inhibiting the enzyme that degrades GLP-1. Which drug was most likely prescribed?